COST-EFFECTIVENESS OF REPLACING THE SEQUENCE PCV13/PPV23 WITH PCV20 IN THE FRENCH ADULT PNEUMOCOCCAL VACCINATION PROGRAM

被引：0
|
作者：
Fievez, S. [1 ]
Blanc, E. [1 ]
Bougeois, M. [1 ]
Sivignon, M. [2 ]
Supiot, R. [3 ]
Vietri, J. [4 ]
Perdrizet, J. [4 ]
Bellier, L. [3 ]
机构：
[1] Pfizer SAS France, Paris, France
[2] Putnam PHMR, Lyon, France
[3] Putnam PHMR, Paris, France
[4] Pfizer Inc, Collegeville, PA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE143
引用
收藏
页码：S78 / S78
页数：1
相关论文
共 50 条
  • [31] A COMPARISON OF THE COST-EFFECTIVENESS OF THE 13-VALENT (PCV13) AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN THE UK
    Patel, R.
    Stoykova, B.
    Lloyd, A. C.
    Willingham, J.
    Hollingsworth, R.
    VALUE IN HEALTH, 2009, 12 (07) : A428 - A428
  • [32] Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
    Atwood, Mark
    Beausoleil, Linda
    Breton, Marie-Claude
    Laferriere, Craig
    Sato, Reiko
    Weycker, Derek
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2018, 109 (5-6): : 756 - 768
  • [33] Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
    Mark Atwood
    Linda Beausoleil
    Marie-Claude Breton
    Craig Laferriere
    Reiko Sato
    Derek Weycker
    Canadian Journal of Public Health, 2018, 109 : 756 - 768
  • [34] COST-EFFECTIVENESS ANALYSIS OF PCV20 3+1 VERSUS PCV15 2+1 VACCINATION OF THE PEDIATRIC POPULATION IN THE NETHERLANDS
    Ta, A.
    Vinand, E.
    Peters, M.
    Cakar, E.
    Ilic, A.
    Perdrizet, J.
    VALUE IN HEALTH, 2024, 27 (12) : S111 - S111
  • [35] COST EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT (PCV13) AND 23-VALENT (PPSV23) PNEUMOCOCCAL VACCINES FOR ADULTS IN A PRIVATE COLOMBIAN INSTITUTION
    Ordonez Molina, J. E.
    Gutierrez-Ardila, M., V
    Vargas Zea, N.
    VALUE IN HEALTH, 2013, 16 (03) : A90 - A90
  • [36] A BUDGET IMPACT (BI) ANALYSIS OF VACCINATING THE ELDERLY AND AT-RISK ADULTS WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO NO VACCINATION (NOVAC) OR 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN THE UK
    Jiang, Y.
    Gauthier, A.
    Keeping, S. T.
    Carroll, S. M.
    VALUE IN HEALTH, 2012, 15 (07) : A388 - A388
  • [37] COST-EFFECTIVENESS ANALYSIS OF THE USE OF THE 20VALENT ANTI-PNEUMOCOCCAL VACCINE (PCV20) IN THE SPANISH PEDIATRIC POPULATION
    Lopez, A.
    Ta, A.
    Galvez, P.
    Perdrizet, J.
    VALUE IN HEALTH, 2024, 27 (12)
  • [38] COST-EFFECTIVENESS ANALYSIS OF JOINT VACCINATION WITH 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND INFLUENZA VACCINE IN TAIWAN DURING SEASONAL INFLUENZA
    Wu, D. B. C.
    Chong, H. Y.
    Lee, K. K. C.
    VALUE IN HEALTH, 2014, 17 (03) : A273 - A273
  • [39] Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination
    Chen, C.
    Beutels, P.
    Newall, A. T.
    VACCINE, 2018, 36 (16) : 2057 - 2060
  • [40] Comparison of PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccine coverage of invasive Streptococcus pneumoniae isolate serotypes in Canada: the SAVE study, 2011-20
    Schellenberg, John J.
    Adam, Heather J.
    Baxter, Melanie R.
    Karlowsky, James A.
    Golden, Alyssa R.
    Martin, Irene
    Demczuk, Walter
    Mulvey, Michael R.
    Zhanel, George G.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 : I37 - I47
12345